热休克蛋白及促炎症细胞因子在前列腺增生合并前列腺炎发生中相关机制的研究
|
摘要
第一部分良性前列腺增生症伴组织学炎症相关因素分析
目的:分析比较前列腺增生患者合并组织学前列腺炎与单纯前列腺增生患者的相关因素，为临床治疗提供可行的依据。
方法:将因尿潴留或LUTS而行TURP的60位住院患者，根据组织病理学诊断，分为前列腺增生合并前列腺炎组45例和单纯前列腺增生组15例，术前对患者年龄、尿潴留史、合并症、国际前列腺症状评分(IPSS)、生活质量评分（QOL）、前列腺体积、残余尿量、最大尿流率Qmax、PSA、血清C反应蛋白(CRP)、血液中白细胞总数、尿液中白细胞计数等分别认真检测并详细记录。
结果:
1两组患者合并症比较：单纯BPH组有尿潴留病史患者例数（2/15，13%）低于前列腺增生合并炎症组（18/45，40%）（P <0.05）；并且单纯BPH组中合并糖尿病患者例数（3/15，20%）低于炎症组（18/45，40%）（P <0.05），合并高血压在BPH组（7/15，47%），BPH合并炎症组（20/45，44%），合并冠心病在BPH组（4/15，27%），BPH合并炎症组（8/45，18%），合并高脂血症在BPH组（6/15，40%），BPH合并炎症组（17/45，38%），两组之间无统计学差异（P>0.05）。
2两组患者一般资料比较：两组患者平均年龄之间有统计学差异，其中单纯BPH组年龄（69.5±5.4）高于炎症组（63.4±3.8）（P <0.05）；炎症组IPSS和QOL评分（28.6±5.2，5.2±0.8）高于单纯BPH组（23.7±4.5，4.2±1.3）（P <0.05），BPH合并炎症组病例残余尿RUV（249.6±14.9ml）、最大尿流率Qmax（5.2±2.4）、前列腺体积（66.8±21.3ml）与BPH组相比(157.5±21.1ml，7.8±2.1ml/s，54.4±18.7ml)均有统计学差异（P<0.05），其中炎症组病例残余尿及前列腺体积均大于单纯增生组，而最大尿流率低于单纯增生组。
3两组患者血PSA.CRP及血尿白细胞计数比较：BPH合并炎症组PSA和CRP（5.3±2.1ng/L，4.4±2.7mg/L）高于BPH组（3.1±1.2ng/L，0.2±1.30mg/L），BPH合并炎症组血尿常规白细胞计数(5.1±2.1×109/L，2.8±1.3/HP)与BPH组（4.6±1.9×109/L，2.6±1.5/HP）比较无统计学差异（P>0.05）。
结论:
1合并前列腺组织学炎症的前列腺增生患者，其尿潴留发生率，前列腺体积，IPSS,QOL评分，血PSA等均明显高于单纯增生组，提示前列腺炎可能促进前列腺增生的发展进程。
2血C反应蛋白（CRP）作为可选择性的血清标志物，术前检测CRP可间接了解前列腺增生症是否合并前列腺炎。
3炎症组中糖尿病发生率升高，提示代谢性疾病可能与前列腺增生合并前列腺炎有某些相关性。
第二部分促炎症细胞因子在前列腺增生症伴组织学炎症中表达的研究
目的:探讨患者前列腺组织及血清中肿瘤坏死因子α(TNF-α)、白细胞介素6(IL-6)以及CD3的表达及临床意义。
方法:60名因尿潴留或LUTS行TURP手术的BPH患者，根据病理诊断分为单纯前列腺增生组（15例）及前列腺中增生合并单纯前列腺炎组（45例），分组与第一部分相同。收集患者一般资料，TURP术中取前列腺组织,立即放入液氮灌中，转-80C°低温冰箱中保存，两组病例标本分别采用蛋白印迹方法（western-blotting）测定组织中TNF-α、IL-6以及CD3的含量。术前空腹抽取静脉血3ml，ELISA测定血清中TNF-α、IL-6的含量，并应用免疫组织化学方法定位检测TNF-α、IL-6以及CD3在前列腺组织中的表达定位情况。
结果:免疫组织化学染色结果显示BPH合并炎症组TNF-α、IL-6、CD3表达MOD值（0.0524±0.04，0.0334±0.024，0.0365±0.009）高于BPH组（0.0323±0.6，0.204±0.016，0.0223±0.003），western-blot方法检测结果显示BPH合并炎症组TNF-α、IL-6、CD3表达相对量(0.24±0.04，0.07±0.04，0.33±0.09)高于BPH组(0.19±0.06，0.04±0.02，0.27±0.06)，ELISA结果亦显示BPH合并炎症组血清中TNF-α、IL-6浓度(34.92±5.1ng/ml，22.07±14.32ng/ml)高于BPH组(24.05±11.5ng/ml，11.05±3.45ng/ml)。尿潴留组各促炎症细胞因子含量明显高于LUTS组，高IPSS评分组各促炎症细胞因子含量高于低IPSS评分组。前列腺增生症合并不同程度炎症之间各促炎症细胞因子亦存在统计学差异，以重度炎症升高最为显著。
结论:
前列腺增生合并前列腺炎时，局部前列腺组织中TNF-α、IL-6、CD3含量均升高，血清中TNF-α及IL-6亦升高，尿潴留及高IPSS评分时前列腺局部组织及血清中TNF-α及IL-6均升高，提示炎症刺激下促炎因子表达明显增多，使前列腺上皮及间质细胞增殖，导致前列腺体积增大，促进临床症状进展。TNF-α、IL-6、CD3可作为评价下尿路症状病情程度的分子生物学指标。
第三部分热休克蛋白27在前列腺增生伴组织学炎症中的表达研究
目的:讨前列腺增生症合并炎症患者前列腺组织及血清中热休克蛋白27表达及临床意义。
方法:60名TURP手术的BPH患者，分为单纯前列腺增生组（15例）及前列腺中增生合并单纯前列腺炎组（45例），分组同第一部分，收集患者一般资料，TURP术中取前列腺组织，立即放入液氮灌中，后转入-80C°低温冰箱中保存，采用western-blotting测定组织中HSP27的含量，ELISA测定血清中HSP27的含量，并应用免疫组织化学方法定位检测HSP27在前列腺组织中的表达定位情况。比较HSP27的表达在前列腺增生合并炎症组与单纯前列腺增生组，尿潴留组和LUTS组，高IPSS和低IPSS组的差异，不同程度炎症组之间差异，并与TNF-α、IL-6、CD3表达进行相关性分析。
结果:
1免疫组织化学染色方法显示，前列腺增生合并组织学炎症组中HSP27MOD值（0.0574±0.13）高于单纯增生组（0.0427±0.062），在尿潴留组中MOD值（0.0596±0.012）高于LUTS组（0.0236±0.04），在高IPSS组中（0.0545±0.014）高于低LUTS组（0.0321±0.12）。统计学有显著性差异。（P <0.01）。前列腺增生合并不同程度炎症之间亦存在统计学差异，以重度炎症升高最为显著。HSF27表达升高与TNF-α、IL-6表达有关。
2western-blotting方法结果显示，HSP27在炎症组中测定值（0.41±0.13）高于单纯增生组（0.27±0.06），在尿潴留组中测定值为（0.44±0.12）高于LUTS组（0.23±0.04），HSP27在高IPSS组（0.45±0.14）高于低LUTS组（0.21±0.12）。
3ELISA测定血清中HSP27浓度，在炎症组（156.86±64.4ng/ml）高于单纯增生组（97.10±48.19ng/ml），在尿潴留组（144.65±45.28ng/ml）高于LUTS组（102.28±50.37ng/ml），在高IPSS组（146.23±38.57ng/ml）高于低LUTS组（103.48±53.82ng/ml）。差异有统计学意义。（P<0.05）。
结论:
1前列腺增生合并前列腺炎组前列腺组织及血清中HSP27含量高于单纯增生组,尿潴留组及高IPSS组亦高于LUTS组及低IPSS组，说明小分子HSP27可能作为分子伴侣在炎症反应刺激下促使前列腺增生症病程进展，并出现相应的临床症状。
2前列腺增生合并组织学炎症时HSP27的升高与促炎症因子TNF-α及IL-6的升高有明显相关性，并且尿潴留时，HSP27升高与TNF-α、IL-6升高亦有明显相关性，说明在前列腺增生合并慢性炎症的发病机制中，HSP27与促炎症细胞因子可能存在相互诱导的关系，其分子学信号传导途径有待进一步研究。
PART Relative factor analysis of benign prostatic hyperplasiaassociated with histological prostatitis
Objective： To provide feasible basis for clinical treatment throughanalysing and comparing relative factors of patients with benign prostatichyperplasia, and patients with benign prostatic hyperplasia and histologicalprostatitis.
Methods： According to histopathological diagnosis, hospitalizedpatients(60cases) were divided into two groups,prostatic hyperplasia withprostatitis group (45cases) and BPH group(15cases). These60cases werereceived TURP surgical treatment due to urinary retention or LUTS.All dataincluding the patients' age, history of urinary retention, complications, theinternational prostate symptom score (IPSS), quality of life score (QOL), andprostate volume, residual urine volume, maximum urine flow rate (Qmax),PSA, serum c-reactive protein (CRP), the total number of white blood cells inthe blood, white blood cell count in urine and other clinical parameters werecollected and compared.
Results：
1Comparing two groups of patients with complications: the cases(2/15,13%) with a history of urinary retention in simple BPH group werelower than the cases (18/45,40%) in BPH with inflammation group (P <0.05);the cases of diabetes mellitus in group of simple BPH patients weresignificantly lower than inflammation group (P <0.05), and othercomplications such as hypertension, coronary heart disease andhyperlipidemia between the two groups had no significant difference (P>0.05).
2General data comparison in two groups of patients: there weresignificant differences between two groups of patients in average age, Theaverage age among BPH patient was higher than that in BPH withinflammation group (P<0.05); IPSS and QOL score in inflammation groupwas higher than the score in BPH group (P<0.05), RUV, maximum urinaryflow rate (Qmax) and residual urine prostatic volume had significantdifference (P<0.05) between the two groups, the average residual urine andprostate volume in inflammation group were greater than BPH group, and themaximum urine flow rate was lower than that in BPH group.
3Comparison of the PSA,CRP level and leucocyte counts in blood andurine in two groups: the leucocyte counts in the routine examination of bloodand urine between the two groups was no significant difference (P>0.05);The level of PSA and CRP in BPH with prostatic inflammation groupwere higher than that in simple BPH group (P<0.05).
Conclusions：
1The incidence of urinary retention, prostate volume, IPSS, QOL score,the level of blood PSA in BPH with histological prostatitis group weresignificantly higher than that of simple BPH. Prostatitis may promote theclinical progress of BPH, and increase the chance of surgical treatment inpatients with BPH.
2Elevation of plasma C-reactive protein level in BPHwith prostatitisindicates prostatitis may be a systemic inflammatory response, CRP can beused as a clinical preoperative serum marker of selectivity of the existence ofprostatitis.
3The increased incidence of diabetes mellitus in BPH with prosttitisindicated that metabolic disease may have a promoting effect on BPH withprostatitis.
Part Ⅱ Association and expression study of proinflammatorycytokins in BPH with prostatitis
Objective: To study the expression and clinical significance ofproinflammatory cytokins:tumor necrosis factor alpha (TNF-α), interleukin6 (IL-6) and CD3in prostate tissue and serum in60cases which received TURPsurgical treatment due to urinary retention or LUTS.
Methods:60patients who received TURP surgery for urinary retentionor LUTS BPH patients, divided into BPH group (15cases) and BPH withprostatitis group (45cases), The patients's general information were collected.Prostate tissue was obtained from the transition zone of the urethra duringTURP process,then immediately stored in the-80°c condition. Tumor necrosisfactor alpha (TNF-α), interleukin6(IL-6), and the content of CD3detectedthrough western blot method in prostate tissue and enzyme-linkedimmunosorbent assay (ELISA) in serum.and tumor necrosis factor alpha(TNF-α), the levels of interleukin6(IL-6). And expression of TNF-α, IL-6andCD3were detected through immunohistochemical method to insure site ofthese in prostate tissue.The BPH and BPH with prostatitis groups,urinaryretention and LUTS groups, high IPSS and low IPSS groups were compared inthe expression of TNF-α,IL-6,CD3in prostatic tissue and plasma.
Results: Expression of TNF-α,IL-6,CD3in BPH with histologicalinflammation group is significantly higher than that in BPH. Proinflammatorycytokins levels in urinary retention group was significantly higher than thatof LUTS group, Expression of TNF-α,IL-6,CD3in high IPSS group (IPSS>25)was higher than low IPSS group(IPSS19-25). Expression of TNF-α,IL-6,CD3among Mild, moderate, severe inflammation in BPH also had significantlystatistical differences.Expression of TNF-α,IL-6,CD3in severe inflammationin BPH was highest.
Conclusion: TNF-α,IL–6,CD3levels increased in BPH with prostatitis inlocal prostate tissue, the serum TNF–α and IL-6also increased. TNF-α,IL–6levels also increased in the urinary retention and high IPSS score groups inlocal prostate tissue and serum. Proinflammatory factor,TNF-α and IL-6,CD3were significantly increased in inflammatory stimuli reaction, they mayparticipate in the pathogenesis of chronic inflammation in prostate hyperplasiaand was induced by proinflammatory factor they could be used as evaluationof molecular biology in low urinary tract symptoms.
Part Ⅲ Association and expression study of heat shock protein27inBPH with prostatitis
Objective: To study the expression and clinical significance of heatshock protein27in prostate tissue and serum of patients in BPH and BPHwith prostatitis groups
Methods:60patients who received TURP surgery for urinary retentionor LUTS BPH patients, divided into BPH group (15cases) and BPH withprostatitis group (45cases).Prostate tissue was obtained from the transitionzone of the urethra during TURP process,then immediately stored in the-80°ccondition.HSP27was detected through western blot andimmunohistochemical staining methods in prostate tissue and enzyme-linkedimmunosorbent assay (ELISA) in serum.The BPH and BPH with prostatitisgroups,urinary retention and LUTS groups, high IPSS and low IPSS groupswere compared in the expression of HSP27in prostatic tissue and plasma.Thecorrelation analysis of the expression of HSP27with TNF-alpha, IL-6,CD3was underwent in BPH and BPH with prostatitis groups.
Results: Expression of HSP27in BPH with histological inflammationgroup was significantly higher than that in BPH. HSP27levels in urinaryretention group was significantly higher than that of LUTS group, Expressionof HSP27in high IPSS group (IPSS>25) was higher than low IPSSgroup(IPSS19-25).Expression of HSP27among Mild, moderate, severeinflammation in BPH also had significantly statistical differences.Expressionof HSP27in severe inflammation in BPH was highest in three different degreeinflammation.
Conclusions:
1HSP27expression in BPH with prostatitis group was higher than that ofBPH group, and it in urinary retention and high IPSS group was higher thanthat in LUTS group and the low IPSS group, small molecule HSP27may be asa molecular chaperone to participate in the pathogenesis of inflammationstimulation to the prostate in BPH clinical symptoms progress.
2The rise of TNF-α,IL-6,CD3in BPH with prostatitis had obviously correlation with HSP27.The molecular signaling pathway was needed furtherresearched about the relationship between HSP27and proinflammatoryfactors.
目的:分析比较前列腺增生患者合并组织学前列腺炎与单纯前列腺增生患者的相关因素，为临床治疗提供可行的依据。
方法:将因尿潴留或LUTS而行TURP的60位住院患者，根据组织病理学诊断，分为前列腺增生合并前列腺炎组45例和单纯前列腺增生组15例，术前对患者年龄、尿潴留史、合并症、国际前列腺症状评分(IPSS)、生活质量评分（QOL）、前列腺体积、残余尿量、最大尿流率Qmax、PSA、血清C反应蛋白(CRP)、血液中白细胞总数、尿液中白细胞计数等分别认真检测并详细记录。
结果:
1两组患者合并症比较：单纯BPH组有尿潴留病史患者例数（2/15，13%）低于前列腺增生合并炎症组（18/45，40%）（P <0.05）；并且单纯BPH组中合并糖尿病患者例数（3/15，20%）低于炎症组（18/45，40%）（P <0.05），合并高血压在BPH组（7/15，47%），BPH合并炎症组（20/45，44%），合并冠心病在BPH组（4/15，27%），BPH合并炎症组（8/45，18%），合并高脂血症在BPH组（6/15，40%），BPH合并炎症组（17/45，38%），两组之间无统计学差异（P>0.05）。
2两组患者一般资料比较：两组患者平均年龄之间有统计学差异，其中单纯BPH组年龄（69.5±5.4）高于炎症组（63.4±3.8）（P <0.05）；炎症组IPSS和QOL评分（28.6±5.2，5.2±0.8）高于单纯BPH组（23.7±4.5，4.2±1.3）（P <0.05），BPH合并炎症组病例残余尿RUV（249.6±14.9ml）、最大尿流率Qmax（5.2±2.4）、前列腺体积（66.8±21.3ml）与BPH组相比(157.5±21.1ml，7.8±2.1ml/s，54.4±18.7ml)均有统计学差异（P<0.05），其中炎症组病例残余尿及前列腺体积均大于单纯增生组，而最大尿流率低于单纯增生组。
3两组患者血PSA.CRP及血尿白细胞计数比较：BPH合并炎症组PSA和CRP（5.3±2.1ng/L，4.4±2.7mg/L）高于BPH组（3.1±1.2ng/L，0.2±1.30mg/L），BPH合并炎症组血尿常规白细胞计数(5.1±2.1×109/L，2.8±1.3/HP)与BPH组（4.6±1.9×109/L，2.6±1.5/HP）比较无统计学差异（P>0.05）。
结论:
1合并前列腺组织学炎症的前列腺增生患者，其尿潴留发生率，前列腺体积，IPSS,QOL评分，血PSA等均明显高于单纯增生组，提示前列腺炎可能促进前列腺增生的发展进程。
2血C反应蛋白（CRP）作为可选择性的血清标志物，术前检测CRP可间接了解前列腺增生症是否合并前列腺炎。
3炎症组中糖尿病发生率升高，提示代谢性疾病可能与前列腺增生合并前列腺炎有某些相关性。
第二部分促炎症细胞因子在前列腺增生症伴组织学炎症中表达的研究
目的:探讨患者前列腺组织及血清中肿瘤坏死因子α(TNF-α)、白细胞介素6(IL-6)以及CD3的表达及临床意义。
方法:60名因尿潴留或LUTS行TURP手术的BPH患者，根据病理诊断分为单纯前列腺增生组（15例）及前列腺中增生合并单纯前列腺炎组（45例），分组与第一部分相同。收集患者一般资料，TURP术中取前列腺组织,立即放入液氮灌中，转-80C°低温冰箱中保存，两组病例标本分别采用蛋白印迹方法（western-blotting）测定组织中TNF-α、IL-6以及CD3的含量。术前空腹抽取静脉血3ml，ELISA测定血清中TNF-α、IL-6的含量，并应用免疫组织化学方法定位检测TNF-α、IL-6以及CD3在前列腺组织中的表达定位情况。
结果:免疫组织化学染色结果显示BPH合并炎症组TNF-α、IL-6、CD3表达MOD值（0.0524±0.04，0.0334±0.024，0.0365±0.009）高于BPH组（0.0323±0.6，0.204±0.016，0.0223±0.003），western-blot方法检测结果显示BPH合并炎症组TNF-α、IL-6、CD3表达相对量(0.24±0.04，0.07±0.04，0.33±0.09)高于BPH组(0.19±0.06，0.04±0.02，0.27±0.06)，ELISA结果亦显示BPH合并炎症组血清中TNF-α、IL-6浓度(34.92±5.1ng/ml，22.07±14.32ng/ml)高于BPH组(24.05±11.5ng/ml，11.05±3.45ng/ml)。尿潴留组各促炎症细胞因子含量明显高于LUTS组，高IPSS评分组各促炎症细胞因子含量高于低IPSS评分组。前列腺增生症合并不同程度炎症之间各促炎症细胞因子亦存在统计学差异，以重度炎症升高最为显著。
结论:
前列腺增生合并前列腺炎时，局部前列腺组织中TNF-α、IL-6、CD3含量均升高，血清中TNF-α及IL-6亦升高，尿潴留及高IPSS评分时前列腺局部组织及血清中TNF-α及IL-6均升高，提示炎症刺激下促炎因子表达明显增多，使前列腺上皮及间质细胞增殖，导致前列腺体积增大，促进临床症状进展。TNF-α、IL-6、CD3可作为评价下尿路症状病情程度的分子生物学指标。
第三部分热休克蛋白27在前列腺增生伴组织学炎症中的表达研究
目的:讨前列腺增生症合并炎症患者前列腺组织及血清中热休克蛋白27表达及临床意义。
方法:60名TURP手术的BPH患者，分为单纯前列腺增生组（15例）及前列腺中增生合并单纯前列腺炎组（45例），分组同第一部分，收集患者一般资料，TURP术中取前列腺组织，立即放入液氮灌中，后转入-80C°低温冰箱中保存，采用western-blotting测定组织中HSP27的含量，ELISA测定血清中HSP27的含量，并应用免疫组织化学方法定位检测HSP27在前列腺组织中的表达定位情况。比较HSP27的表达在前列腺增生合并炎症组与单纯前列腺增生组，尿潴留组和LUTS组，高IPSS和低IPSS组的差异，不同程度炎症组之间差异，并与TNF-α、IL-6、CD3表达进行相关性分析。
结果:
1免疫组织化学染色方法显示，前列腺增生合并组织学炎症组中HSP27MOD值（0.0574±0.13）高于单纯增生组（0.0427±0.062），在尿潴留组中MOD值（0.0596±0.012）高于LUTS组（0.0236±0.04），在高IPSS组中（0.0545±0.014）高于低LUTS组（0.0321±0.12）。统计学有显著性差异。（P <0.01）。前列腺增生合并不同程度炎症之间亦存在统计学差异，以重度炎症升高最为显著。HSF27表达升高与TNF-α、IL-6表达有关。
2western-blotting方法结果显示，HSP27在炎症组中测定值（0.41±0.13）高于单纯增生组（0.27±0.06），在尿潴留组中测定值为（0.44±0.12）高于LUTS组（0.23±0.04），HSP27在高IPSS组（0.45±0.14）高于低LUTS组（0.21±0.12）。
3ELISA测定血清中HSP27浓度，在炎症组（156.86±64.4ng/ml）高于单纯增生组（97.10±48.19ng/ml），在尿潴留组（144.65±45.28ng/ml）高于LUTS组（102.28±50.37ng/ml），在高IPSS组（146.23±38.57ng/ml）高于低LUTS组（103.48±53.82ng/ml）。差异有统计学意义。（P<0.05）。
结论:
1前列腺增生合并前列腺炎组前列腺组织及血清中HSP27含量高于单纯增生组,尿潴留组及高IPSS组亦高于LUTS组及低IPSS组，说明小分子HSP27可能作为分子伴侣在炎症反应刺激下促使前列腺增生症病程进展，并出现相应的临床症状。
2前列腺增生合并组织学炎症时HSP27的升高与促炎症因子TNF-α及IL-6的升高有明显相关性，并且尿潴留时，HSP27升高与TNF-α、IL-6升高亦有明显相关性，说明在前列腺增生合并慢性炎症的发病机制中，HSP27与促炎症细胞因子可能存在相互诱导的关系，其分子学信号传导途径有待进一步研究。
PART Relative factor analysis of benign prostatic hyperplasiaassociated with histological prostatitis
Objective： To provide feasible basis for clinical treatment throughanalysing and comparing relative factors of patients with benign prostatichyperplasia, and patients with benign prostatic hyperplasia and histologicalprostatitis.
Methods： According to histopathological diagnosis, hospitalizedpatients(60cases) were divided into two groups,prostatic hyperplasia withprostatitis group (45cases) and BPH group(15cases). These60cases werereceived TURP surgical treatment due to urinary retention or LUTS.All dataincluding the patients' age, history of urinary retention, complications, theinternational prostate symptom score (IPSS), quality of life score (QOL), andprostate volume, residual urine volume, maximum urine flow rate (Qmax),PSA, serum c-reactive protein (CRP), the total number of white blood cells inthe blood, white blood cell count in urine and other clinical parameters werecollected and compared.
Results：
1Comparing two groups of patients with complications: the cases(2/15,13%) with a history of urinary retention in simple BPH group werelower than the cases (18/45,40%) in BPH with inflammation group (P <0.05);the cases of diabetes mellitus in group of simple BPH patients weresignificantly lower than inflammation group (P <0.05), and othercomplications such as hypertension, coronary heart disease andhyperlipidemia between the two groups had no significant difference (P>0.05).
2General data comparison in two groups of patients: there weresignificant differences between two groups of patients in average age, Theaverage age among BPH patient was higher than that in BPH withinflammation group (P<0.05); IPSS and QOL score in inflammation groupwas higher than the score in BPH group (P<0.05), RUV, maximum urinaryflow rate (Qmax) and residual urine prostatic volume had significantdifference (P<0.05) between the two groups, the average residual urine andprostate volume in inflammation group were greater than BPH group, and themaximum urine flow rate was lower than that in BPH group.
3Comparison of the PSA,CRP level and leucocyte counts in blood andurine in two groups: the leucocyte counts in the routine examination of bloodand urine between the two groups was no significant difference (P>0.05);The level of PSA and CRP in BPH with prostatic inflammation groupwere higher than that in simple BPH group (P<0.05).
Conclusions：
1The incidence of urinary retention, prostate volume, IPSS, QOL score,the level of blood PSA in BPH with histological prostatitis group weresignificantly higher than that of simple BPH. Prostatitis may promote theclinical progress of BPH, and increase the chance of surgical treatment inpatients with BPH.
2Elevation of plasma C-reactive protein level in BPHwith prostatitisindicates prostatitis may be a systemic inflammatory response, CRP can beused as a clinical preoperative serum marker of selectivity of the existence ofprostatitis.
3The increased incidence of diabetes mellitus in BPH with prosttitisindicated that metabolic disease may have a promoting effect on BPH withprostatitis.
Part Ⅱ Association and expression study of proinflammatorycytokins in BPH with prostatitis
Objective: To study the expression and clinical significance ofproinflammatory cytokins:tumor necrosis factor alpha (TNF-α), interleukin6 (IL-6) and CD3in prostate tissue and serum in60cases which received TURPsurgical treatment due to urinary retention or LUTS.
Methods:60patients who received TURP surgery for urinary retentionor LUTS BPH patients, divided into BPH group (15cases) and BPH withprostatitis group (45cases), The patients's general information were collected.Prostate tissue was obtained from the transition zone of the urethra duringTURP process,then immediately stored in the-80°c condition. Tumor necrosisfactor alpha (TNF-α), interleukin6(IL-6), and the content of CD3detectedthrough western blot method in prostate tissue and enzyme-linkedimmunosorbent assay (ELISA) in serum.and tumor necrosis factor alpha(TNF-α), the levels of interleukin6(IL-6). And expression of TNF-α, IL-6andCD3were detected through immunohistochemical method to insure site ofthese in prostate tissue.The BPH and BPH with prostatitis groups,urinaryretention and LUTS groups, high IPSS and low IPSS groups were compared inthe expression of TNF-α,IL-6,CD3in prostatic tissue and plasma.
Results: Expression of TNF-α,IL-6,CD3in BPH with histologicalinflammation group is significantly higher than that in BPH. Proinflammatorycytokins levels in urinary retention group was significantly higher than thatof LUTS group, Expression of TNF-α,IL-6,CD3in high IPSS group (IPSS>25)was higher than low IPSS group(IPSS19-25). Expression of TNF-α,IL-6,CD3among Mild, moderate, severe inflammation in BPH also had significantlystatistical differences.Expression of TNF-α,IL-6,CD3in severe inflammationin BPH was highest.
Conclusion: TNF-α,IL–6,CD3levels increased in BPH with prostatitis inlocal prostate tissue, the serum TNF–α and IL-6also increased. TNF-α,IL–6levels also increased in the urinary retention and high IPSS score groups inlocal prostate tissue and serum. Proinflammatory factor,TNF-α and IL-6,CD3were significantly increased in inflammatory stimuli reaction, they mayparticipate in the pathogenesis of chronic inflammation in prostate hyperplasiaand was induced by proinflammatory factor they could be used as evaluationof molecular biology in low urinary tract symptoms.
Part Ⅲ Association and expression study of heat shock protein27inBPH with prostatitis
Objective: To study the expression and clinical significance of heatshock protein27in prostate tissue and serum of patients in BPH and BPHwith prostatitis groups
Methods:60patients who received TURP surgery for urinary retentionor LUTS BPH patients, divided into BPH group (15cases) and BPH withprostatitis group (45cases).Prostate tissue was obtained from the transitionzone of the urethra during TURP process,then immediately stored in the-80°ccondition.HSP27was detected through western blot andimmunohistochemical staining methods in prostate tissue and enzyme-linkedimmunosorbent assay (ELISA) in serum.The BPH and BPH with prostatitisgroups,urinary retention and LUTS groups, high IPSS and low IPSS groupswere compared in the expression of HSP27in prostatic tissue and plasma.Thecorrelation analysis of the expression of HSP27with TNF-alpha, IL-6,CD3was underwent in BPH and BPH with prostatitis groups.
Results: Expression of HSP27in BPH with histological inflammationgroup was significantly higher than that in BPH. HSP27levels in urinaryretention group was significantly higher than that of LUTS group, Expressionof HSP27in high IPSS group (IPSS>25) was higher than low IPSSgroup(IPSS19-25).Expression of HSP27among Mild, moderate, severeinflammation in BPH also had significantly statistical differences.Expressionof HSP27in severe inflammation in BPH was highest in three different degreeinflammation.
Conclusions:
1HSP27expression in BPH with prostatitis group was higher than that ofBPH group, and it in urinary retention and high IPSS group was higher thanthat in LUTS group and the low IPSS group, small molecule HSP27may be asa molecular chaperone to participate in the pathogenesis of inflammationstimulation to the prostate in BPH clinical symptoms progress.
2The rise of TNF-α,IL-6,CD3in BPH with prostatitis had obviously correlation with HSP27.The molecular signaling pathway was needed furtherresearched about the relationship between HSP27and proinflammatoryfactors.
引文
1Nickel JC.Prostatic inflammation in benign prostatic hyperplasia the thirdcomponent? Can J Urol1994,1:1~4
2Nickel JC. The overlapping lower urinary tract symptoms of benignprostatic hyperplasia and prostatitis[J].Current Opinion in Urology2006,16,5~10
3Nickel JC.Inflammation and benign prostatic hyperplasia[J]. Urol Clin NAm2008,35,109~115
4Nickel JC, Downey J,Young I.et al. Asymptomatic inflammation and orinfection in benign prostatic hyperplasia[J]. BJU Int1999,84,976~981
5Nickel JC,Downey J,Pontari MA,et al.A randomized placebo-controlledmulticentre study to evaluate the safety and efficacy of finasteride for malechronic pelvic pain syndrome (category IIIA chronic nonbacterialprostatitis)[J]. BJU Int.2004,93,991~995
6St Sauver JL,Jacobson DJ,McGree ME.et al. Protective associationbetween nonsteroidal anti-inflammatory drug use and measures of benignprostatic hyperplasia[J].American Journal of Epidemiology2006,164,760~768
7McConnell JD,Roehrborn CG,Bautista OM, et al. The long term effect ofdoxazosine, finasteride and combination therapy on the clinicalprogression of benign prostatic hyperplasia[J]. New England Journal ofMedicine.2003,349,2387~2398
8Nickel JC,Roehrborn CG, O’Leary MP.et al. The relationship betweenprostate inflammation and lower urinary tract symptoms: examination ofbaseline data from the REDUCE trial[J]. European Urology.2007,54,1379~1384
9Mishra VC, Allen DJ, Nicolaou C, et al. Does intraprostatic inflammationhave a role in the pathogenesis and progression of benign prostatichyperplasia?[J] BJU Int2007;100:327~331
10Van Vuuren SP, Heyns CF, Zarrabi AD.Significance of histologicalprostatitis in patients with urinary retention and underlying benignprostatic hyperplasia or adenocarcinoma of the prostate [J].BJU Int,2012,109(8):1194~1197
11Sciarra A,Mariotti G,Salciccia S,et al.Prostate growth and inflammation[J].J Steroid Biochem Mol Biol2008;108:254~260
12Sciarra A, Di Silverio F, Salciccia S, et al. Inflammation and chronicprostatic diseases: evidence for a link?[J] Eur Urol2007;52:964~972
13Litwin MS,M cNaughton-Collins M,Fowler FJ Jr, et, al. The NationalInstitutes of Health chronic prostatitis symptom index (NIHCPSI):Development and validation of a new outcome measure[J]. JUrol,1999,162(2):369~375
14Nickel JC, True LD, Krieger JN, et al.Consensus development of ahistopathological classification system for chronic prostatic inflammation[J]. BJU Int,2001,87(9):797~805
15夏同礼.现代泌尿病理学.北京:人民卫生出版社,2002.477~480
16张祥华,张骞,李学松,等.良性前列腺增生合并组织学前列腺炎的检出率[J].中华临床医师杂志,2007,1(7):539~541
17Mishra VC,Allen DJ,Nicolaou C,et al.Does intraprostatic inflammationhave a role in the pathogenesis and progression of benign prostatichyperplasia？[J] BJU Int.2007;100(2):327~331
18Nadler RB, Humphrey PA, Smith DS, et al. Effect of inflammation andbenign prostatic hyperplasia on elevated serum prostate specific antigenlevels [J].J Urol.1995;154:407~413
19Nickel JC,Roehrborn CG,O’Leary MP,et al.Examination of therelationship between symptoms of prostatitis and histologicalinflammation: baseline data from the REDUCE chemoprevention trial [J].JUrol.2007;178:896~900
20Seyed AA, Mohaddeseh M. The Role of Intraprostatic Inflammation in theAcute Urinary Retention [J]. Int J Prev Med,2011,2(1):28~31
21Nickel JC, Roehrborn CG, O'Leary MP, et al. The relationship betweenprostate inflammation and lower urinary tract symptoms: examination ofbaseline data from the REDUCE trial[J].Eur Urol,2008,54(6):1379~1384.
22Devaraj S, Singh U, Jialal I.Human C-reactive protein and the metabolicsyndrome. Curr Opin Lipidol2009;20:182~189
23Martin-Cordero L, Garcia JJ, Giraldo E, De la Fuente M, Manso R, OrtegaE.Influence of exercise on the circulating levels and macrophageproduction of IL-1beta and IFN-gamma affected by metabolic syndrome:an obese Zucker rat experimental animal model. Eur J Appl Physiol2009;107:535~543
24Alexandraki K, Piperi C, Kalofoutis C, et al. Inflammatory process in type
2diabetes: the role of cytokines.Ann NY Acad Sci2006;1084:89~117
25Gustafson B, Hammarstedt A, Andersson CX, Smith U. Inflamed adiposetissue: a culprit underlying the metabolic syndrome and atherosclerosis.Arterioscler Thromb Vasc Biol2007;27:2276~2283
26Murdolo G, Smith U. The dysregulated adipose tissue:a connecting linkbetween insulin resistance, type2diabetes mellitus and atherosclerosis.Nutr Metab Cardiovasc Dis.2006;16(Suppl.1):S35~38
27Shun-Fa Hung, Shiu-Dong Chung, Hann-Chorng Kuo，Increased serumC-Reactive Protein level is associated with increased storage lower urinarytract symptoms in men with Benign Prostatic Hyperplasia.PLoS One.2014Jan15;9(1):e85588
28Liao CH,Chung SD,Kuo HC， Serum C-reactive protein levels areassociated with residual urgency symptoms in patients with benignprostatic hyperplasia after medical treatment.Urology.2011;78(6):1373~1378
29Jennifer L.St. Sauver, Aruna V. Sarma, Debra J Jacobson.Associationsbetween C-Reactive Protein and Benign Prostatic Hyperplasia Lowerurinary tract symptom outcomes in a population-based Cohort.Am JEpidemiol2009;169:1281~1290
30St Sauver JL,Jacobson DJ, McGree ME,et al. Protective associationbetween nonsteroidal antiinflammatory drug use and measures of benignprostatic hyperplasia.Am J Epidemiol.2006;164(8):760~768
31Falahatkar S,Mokhtari G,Pourreza F,et al.Celecoxib for treatment ofnocturia caused by benign prostatic hyperplasia: a prospective,randomized,double-blind,placebo-controlled study.Urology.2008;72(4):813~816
32VelaNavarreteR,GarciaCardosoJV A.BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatorymarkers.Results of a double blind pilot clinical assay.Eur Urol2003;44:549~55
1McVary KT. BPH: epidemiology and comorbidities.Am J Manag Care.2006;12(suppl5):S122~S128
2Roehrborn CG. BPH progression: concept and key learning from MTOPS,ALTESS, COMBAT,and ALF-ONE. BJU Int.2008;101(suppl3):17~21
3Vykhovanets EV, Resnick MI，Marengo SR. The healthy rat prostatecontains high levels of natural killer-like cells and unique subsets of CD4+helper-inducer T cells: implications for prostatitis.JUrol.2005;173(3):1004~1010
4Steiner GE, Stix U, Handisurya A.et al. Cytokine expression pattern inbenign prostatic hyperplasia infiltrating T cells and impact of lymphocyticinfiltration on cytokine mRNA profile in prostatic tissue. LaboratoryInvestigation.2003;83：1131~1146
5Sciarra, A., Di Silverio, F., Salsiccia, S,et al.Inflammation and chronicprostatic diseases:evidence for a link? European Urology2007，52,（4）964~972
6Penna G,Fibbi B,Amuchastegui S,et al. Human benign prostatichyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. J Immunol.2009;182(7):4056~4064
7Nadlcr RB，Koch AE，Calhoun EA，et a1．IL-1beta and TNF-alpha inprostatic secretions are indicators in the evaluation of men with chronicprostatitis.J Urol，2000，164(1)：214~218
8贺大林，周锋，何辉等，前列腺按摩液中IL一8和TNF-α测定在慢性前列腺炎诊断、分型中的临床意义。中华男科学杂志，2004,10；（10）740~742
9孙国华，宁方霞，夏玉军。IL一10、TNF-a在前列腺增生及前列腺癌组织中的表达及意义。泌尿外科杂志（电子版）2012，4（1）：25~28
10Pontari M．A，Ruggieri M．R．Mechanisms in prostatitis／chronic pelvicpain．J Urol，2008，179(supply5)：61~67
11Jeannette M. Schenk, Alan R. Kristal, Marian L. Neuhouser,,etal.Biomarkers of systemic inflammation and risk of incident, symptomaticbenign prostatic hyperplasia: results from the prostate cancer preventiontrial. Am J Epidemiol.2010;171(5):571~82
12Giri D, Ozen M，Ittman M.Interleukin-6is an autocrine growth factor inhuman prostate cancer. American Journal of Pathology.2001;159(6):2159~2165
13Royuela M,Ricote M,Parsons MS.et al.Immunohistochemical analysis ofthe IL-6family of cytokines and their receptors in benign hyperplasic, andmalignant human prostate. J Pathol.2004;202(1):41~49
14俞弘颀，孙清，张洲洲。血清白介素及肿瘤坏死因子-α水平在良性前列腺增生与慢性前列腺炎关系探讨中的价值。苏州大学学报（医学版），2008；28（6）：1070~1071
15Bouraoui Y,Ricote M,García-Tu ón I,et al.Pro-inflammatory cytokinesand prostate-specific antigen in hyperplasia and human prostate cancer.Cancer Detect Prev.2008;32(1):23~32
16李兴斌，王海峰，常丛旺。前列腺液IL-6、IL-8在诊断BPH合并CP的临床意义。西部医学，2012；24（2）：250~251
17De Nunzio C,Kramer G,Marberger M,et al. The controversial relationshipbetween benign prostatic hyperplasia and prostate cancer: the role ofinflammation. Eur Urol.2011;60(1):106~117
18Robert G, Descazeaud A, Nicolaiew N, et al. Inflammation in benignprostatic hyperplasia: a282patients immunohistochemical analysis.Prostate2009;69:1774~1780
19El Hentati FZ, Gruy F, Iobagiu C, et al. Variability of CD3MembraneExpression and T Cell Activation Capacity.Cytometry B ClinCytom.2010;78(2):105~114
20Park DS,Shim JY. Histologic influence of doxazosin and finasteride inbenign prostatic hyperplasia accompanying chronic inflammation. UrolInt.2008;81(4):441~446
21蓝儒竹，庄乾元，胡志全等，前列腺增生组织内炎症对前列腺微循环的影响。中华实验外科杂志，2009，26（10）：1366~1368
1Cornford PA, Dodson AR, Parsons KF, et al.Heat shock proteinexpression independently predicts clinical outcome in prostate cancer.Cancer Res2000;60:7099~7105
2Foster CS, Dodson AR, Ambroisine L, et al. Hsp-27expression atdiagnosis predicts poor clinical outcome in prostate cancer independent ofETS-gene rearrangement. Br J Cancer2009;101:1137~1144
3Glaessgen A,Jonmarker S,Lindberg A,et al.Heat shock proteins27,60and70as prognostic markers of prostate cancer.Apmis2008;116:888~895
4Miyake H, Muramaki M, Kurahashi T, et al.Expression of potentialmolecular markers in prostate cancer: correlation with clinicopathologicaloutcomes in patients undergoing radical prostatectomy. Urol Oncol2010;28:145~151
5Shiota M,Bishop JL,Nip KM,et al.Hsp27regulates epithelial mesenchymaltransition,metastasis, and circulating tumor cells in prostate cancer. CancerRes.2013,15(10):3109~3119
6N Vasiljevi,A S Ahmad,C Beesley,et al. Association between DNAmethylation of HSPB1and death in low Gleason score prostate cancer.Prostate Cancer Prostatic Dis.2013;16(1):35~40
7Zoubeidi A,Zardan A,Beraldi E,et al. Cooperative interactions betweenandrogen receptor(AR) and heat-shock protein27facilitate ARtranscriptionalactivity. Cancer Res.2007;67(21):10455~10465
8刘丽娜，牛晓东，李伟等，热休克蛋白27在前列腺癌中的表达及临床意义。解放军医药杂志，2012，24（9）20~22
9Welch WJ,How cells respond to stress.SCI Am.1993;268:56-64
10De Marzo AM, Platz, EA., Sutcliffe S,et al. Inflammation in prostatecarcinogenesis. Nat Rev Cancer2007;7（4）256~269
11陈月云，王伟华，于智勇等，非那雄胺对老年良性前列腺增生患者血清热休克蛋白和肿瘤坏死因子以及白细胞介素影响。中华老年医学杂志，2013；32（1）58~60
12Ali MM,Vaidya V.Vitamin D and cancer.J Cancer Res Ther.2007;3:225~230
13Penna G, Fibbi B, Amuchastegui S,et al.Human Benign prostatichyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. Journal of Immunology2009b,182:4056~4064
14Adorini L, Penna, G., Amuchastegui, S., et al. Inhibition of prostategrowth and inflammation by the vitamin D receptor agonist BXL-628(elocalcitol). Journal of Steroid Biochemistry and Molecular Biology2007；103:689~693
1McVary KT. BPH: epidemiology and comorbidities.Am J Manag Care.2006;12(suppl5):122~128
2Roehrborn CG. BPH progression: concept and key learning from MTOPS,ALTESS, COMBAT,and ALF-ONE.BJU Int.2008;101(suppl3):17~21
3Mishra VC,Allen DJ,Nicolaou C,et al. Does intraprostatic inflammationhave a role in the pathogenesis and progression of benign prostatichyperplasia?BJU Int.2007.Aug;100(2):327~331
4Nadler RB, Humphrey PA, Smith DS, et al. Effect of inflammation andbenign prostatic hyperplasia on elevated serum prostate specific antigenlevels. J Urol.1995;154:407~413
5Nickel JC, Roehrborn CG, O’Leary MP, et al. Examination of therelationship between symptoms of prostatitis and histologicalinflammation: baseline data from the REDUCE chemoprevention trial.JUrol.2007;178:896~900; discussion900~901
6Sciarra, A., Di Silverio, F., Salsiccia, S,et al.. Inflammation and chronicprostatic diseases: evidence for a link? European Urology2007，52,（4）964~972
7Penna G,Fibbi B,Amuchastegui S,et al.Human benign prostatichyperplasia stromal cells as inducers and targets of chronicimmuno-mediated inflammation. J Immunol.2009;182(7):4056~4064
8Zisman, A., Zisman, E., Lindner, A., Velikanov, S., Siegel, Y. I.&Mozes,E. Autoantibodies to prostate specific antigen in patients withbenign prostatic hyperplasia. Journal of Urology (1995)154,1052~1055
9Harrington, L. E., Mangan, P. R.&Weaver, C. T. Expandingthe effectorCD4T-cell repertoir: The Th17lineage. Current Opinion in Immunology.200618,349~356
10Krieger JN,Lee SW,Jeon J,et al. Epidemiology of prostatitis. InternationalJournal of Antimicrobial Agents.2008;31:85~90
11Pontari MA,Ruggieri MR. Mechanisms in prostatitis chronic pelvic painsyndrome. Journal of Urology。2008；179,61~67
12Harris MT,Feldberg RS,Lau KM.,et al. Expression of proinflamma torygenes during estrogeninduced inflammation of the rat prostate. Prostate,2000；44,19~25
13Naslund,M.J.Coffey,D.S.The differential effects of neonatal androgen,estrogen and progesterone on adult rat postate growth..J Urol1986,(136):1136~1140
14Kramer,G.,Mitteregger,D.Marberger,M.Is begign prostatic hyperplasia(BPH) an immune inflammatory disease?European Urology2007,(51):1202~1216
15Sandhu,J.S.Prostate cancer and chronic prostatitis.Curr UrolRep,2008;9(4):328~332
16J Riera CM,Rivero, VE. Presence of IFNc-secreting lymphocytes specificto prostate antigens in a group of chronic prostatitis patients. ClinImmunol.2005;116,149~157
17Vykhovanets, E. V., Resnick, M. I., MacLennan, G. T.&Gupta, S.Experimental rodent models of prostatitis: limitations and potential.Prostate Cancer Prostatic Dis.2007;10,15~29
18Nickel, J. C. Inflammation and benign prostatic hyperplasia. Urol Clin NAm.2008;35,109~115
19Krieger JN, Lee SW,Jeon J,et al.Epidemiology of prostatitis.International.Journal of Antimicrobial Agents.2008;31,85~90
20Alexander RB,Mann DL, Borkowski AA,et al. Granulomatous prostatitislinked to HLA-DRB1*1501. Journal of Urology.2004;171:2326~2329
21Klyushnenkova EN, Link J, Oberle WT,er al. Identification ofHLADRB1*1501-restricted T-cell epitopes from prostate-specificantigen.Clinical Cancer Research.2005;11:2853~2861
22Schwartz GG. Vitamin D and the epidemiology of prostate cancer. SeminDial.2005;18:276~289
23Ali MM,Vaidya,V. Vitamin D and cancer.J Cancer Res Ther2007;3:225~230
24Glenn Liu, George Wilding, Mary Jane Staab,et al.Phase II Study of1-Hydroxyvitamin D2in the Treatment of Advanced Androgen-independent Prostate Cancer.Clin Cancer Res.2003;9:4077~4083
25Maggi M,Crescioli C,Morelli A, er al. Pre-clinical evidence and clinicaltranslation of benign prostatic hyperplasia treatment by the vitamin Dreceptor agonist BXL-628，(Elocalcitol). Journal of EndocrinologicalInvestigation.2006;29,665~674
26Colli E, Rigatti P,Montorsi F,Artibani W,Petta S,Mondaini N.et al.BXL-628, a novel vitamin D3analog arrests prostate growth in patientswith benign prostatic hyperplasia: a randomized clinical trial. EuropeanUrology.2006;49:82~86
27Montorsi F,Colli E,Elocalcitol in the Treatment of BPH: A MulticenterRandomized Placebo-Controlled Phase IIb Clinical Trial. Abstract at theAmerican Urological Association Meeting.2008; Orlando, Florida, USA.
28Mishra VC,Allen DJ,Nicolaou C, et al. Does intraprostatic inflammationhave a role in the pathogenesis and progression of benign prostatichyperplasia? BJU Int.2007;100:327~331
29Nickel JC.Prostatic inflammation in benign prostatic hyperplasia-thethird component?Can J Urol.1994;1:1~4
30Nickel JC. Inflammation and benign prostatic hyperplasia.Urol Clin NorthAm.2008;35:109~115
31Roehrborn, C. G.Pathology of benign prostatic hyperplasia.InternationalJournal of Impotence Research2008,20,11~18
32Kobayashi, Y. The role of chemokines in neutrophil biology.FrontBiosci.2008;13:2400~2407
33Waugh DJ,Wilson C.The interleukin-8pathway in cancer.Clinical CancerResearch.2008;14:6735~6741
34Castro P,Xia C,Gomez L,Lamb DJ,Ittmann M. Interleukin-8expression isincreased in senescent prostatic epithelial cells and promotes thedevelopment of benign prostatic hyperplasia.Prostate.2004;60:153~159
35Schauer IG,Ressler SJ,Tuxhorn JA,et al. Elevated epithelial expression ofinterleukin-8correlates with myofibroblast reactive stroma in benignprostatic hyperplasia.Urology2008;72:205~213
36Penna G, Fibbi B, Amuchastegui S,et al. Human Benign prostatic hyper-plasia stromal cells as inducers and targets of chronic immuno-mediatedinflammation. Journal of Immunology2009b;182:4056~4064
37Penna G,Fibbi B,Amuchastegui S, et al. Human benign prostatichyperplasia stromal cells as inducers and targets of chronicimmune-mediated inflammation.. J Immunol.2009;182(7):4056~4064
38Robert G, Descazeaud A, Nicolaiew N, et al. Inflammation in benignprostatic hyperplasia: a282patients’ immunohistochemical analysis.Prostate.2009;69(16):1774~1780
39Rautajoki KJ,Kylaniemi MK, Raghav SK,et al. An insight into molecularmechanisms of human T helper cell differentiation. Annals of Medicine.2008;40:322~335
40Steiner GE,Djavan B,Kramer G,et al.The picture of the prostaticlymphokine network is becoming increasingly complex. Rev Urol2002;4:171~177
41Steiner GE,Stix U,Handisurya A.et al.Cytokine expression pattern inbenign prostatic hyperplasia infiltrating T cells and impact of lymphocyticinfiltration on cytokine mRNA profile in prostatic tissue.LaboratoryInvestigation.2003;(83):1131~1146
42Linda Vignozzi,Ilaria Cellai,Raffaella Santi,et al,Antiinflammatory effectof androgen receptor activation in human benign prostatic hyperplasiaells.Journal of Endocrinology.2012;214:31~43
43Robert G, Descazeaud A, Nicolaiew N, et al. Inflammation in benignprostatic hyperplasia: a282patients’ immunohistochemical analysis.Prostate.2009;69:1774~1780
44McDowell ME, Occhipinti S, Gardiner RA, et al.A review of prostate-specific antigen screening prevalence and risk perceptions for first-degreerelatives of men with prostate cancer. Eur J Cancer Care (Engl).2009;18:545~555
45Steiner GE, Newman ME, Paikl D, et al. Expression and function ofpro-inflammatory interleukin IL-17and IL-17receptor in normal, benignhyperplastic, and malignant prostate. Prostate.2003;56:171~182
46Descazeaud A，Weinbreck N，Ｒobert G，et al．Transforming growth factorbeta-receptor II protein expression in benign prostatic hyperplasia isassociateed with prostate volume and inflammation［J］BJU Int.2011;108(4):E23~28
47Sugar LM.Inflammation and prostate cancer.Can J Urol.2006;13(suppl1):46~47
48Di Silverio F, Gentile V, De Matteis A, et al.Distribution of inflammation,pre-malignant lesions, incidental carcinoma in histologically confirmedbenign prostatic hyperplasia: a retrospective analysis.Eur Urol.2003;43:164~175
49Falahatkar S, Mokhtari G, Pourreza F, et al. Celecoxib for treatment ofnocturia caused by benign prostatic hyperplasia: a prospective, randomized,double-blind, placebo-controlled study. Urology.2008;72:813~816
50Djavan B，Eckersberger E，Espinosa G，et al． Complex mechanisms inprostatic inflammatory response.［J］Eur Urol，2009，(Suppl8):872~878
51Naslund MJ，Strandberg JD，Coffey DS． The role of androgens andestrogens in the pathogenesis of experimental nonbacterial prostatitis.JUrol，1988，140:1049~1053
52Gervaix A, Galetto-Lacour A, Gueron T, Vadas L, Zamora S, Suter S, etal.Usefulness of procalcitonin and C-reactive protein rapid tests for themanagement of children with urinary tract infection. Pediatr Infect Dis J2001,20:507~511
53Lehrer S, Diamond EJ, Mamkine B, Droller MJ, Stone NN, et al Creactiveprotein is significantly associated with prostate-specific antigen andmetastatic disease in prostate cancer. BJU Int2005,95:961~962
54Shun-Fa Hung, Shiu-Dong Chung, Hann-Chorng Kuo，Increased SerumC-Reactive Protein Level Is Associated with Increased Storage LowerUrinary Tract Symptoms in Men with Benign Prostatic Hyperplasia.PLoSOne.2014Jan15;9(1):e85588
55Liao CH,Chung SD,Kuo HC， Serum C-reactive protein levels areassociated with residual urgency symptoms in patients with benignprostatichyperplasia after medical treatment.Urology.2011;78(6):1373~1378
56Jennifer L St Sauver,Aruna V Sarma, Debra J. Jacobson,.AssociationsBetween C-Reactive Protein and Benign Prostatic Hyperplasia LowerUrinary Tract Symptom Outcomes in a Population-based Cohort。Am JEpidemiol2009;169:1281~1290
57Devaraj S, Singh U, Jialal I. Human C-reactive protein and the metabolicsyndrome. Curr Opin Lipidol2009;20:182~189
58Martin-Cordero L, Garcia JJ, Giraldo E,et al. Influence of exercise on thecirculating levels and macrophage production of IL-1beta and IFNgammaaffected by metabolic syndrome: an obese Zucker rat experimental animalmodel. Eur J Appl Physiol2009;107:535~543
59Alexandraki K, Piperi C, Kalofoutis C,et al. Inflammatory process in type
2diabetes: the role of cytokines.Ann NY Acad Sci2006;1084:89~117
60Gustafson B, Hammarstedt A, Andersson CX, Smith U. Inflamed adiposetissue: a culprit underlying the metabolic syndrome and atherosclerosis.Arterioscler Thromb Vasc Biol2007;27:2276~2283
61Murdolo G, Smith U. The dysregulated adipose tissue:a connecting linkbetween insulin resistance, type2diabetes mellitus and atherosclerosis.Nutr Metab Cardiovasc Dis2006;16(Suppl.1): S35~38
62Bock E, Calugi V, Stolfi V, er al.Calcifications of the prostate: atransrectal echographic study. Radiol Med1989;77:501~503
63Shoskes DA, Lee CT, Murphy D, er al.Incidence and significance ofprostatic stones in men with chronic prostatitis/chronic pelvic painsyndrome.Urology2007;70:235~238
64Geramoutsos I, Gyftopoulos K, Perimenis P et al.Clinical correlation ofprostatic lithiasis with chronic pelvic pain syndromes in young adults. EurUrol2004;45:333~338
65Kwon YK, Choe MS, Seo KW, et al. The effect of intraprostatic chronicinflammation on benign prostatic hyperplasia treatment. Korean J Urol2010;51:266~270
66Hightower LE.Heat shock protein,chaperones and protectoxicity.Cell.1991;66:191~197
67Welch WJ,How cells respond to stress.SCI Am.1993;268:56~64
68Weiss YG,Maloyan A,Tazelaar J，Adenoviral transfer of HSP-70intopulmonary epithelium ameliorates experimental acute respiratory distresssyndrome.J Clin Invest.2002;110(6):801~806
69DeMaio A. Heat shock proteins, oxygen radicals, and apoptosis: theconflict between protection and destruction[J]. Critical care medicine,2000,28(5):1679.~1681
70Diamant S, Ben-Zvi AP,BukauB,etal. Size-dependent disaggregation ofstable protein aggregates by the DnaK chaperone machinery.J BiolChem,2000;275(28);21107~21113
71Thomas Laufen,Matthias P. Mayer,Christian Beisel,et al..Proc Natl AcadSci U S A.1999;96(10):5452~5457
72Schmidt JA,Abdulla E，Down-regulation of IL-1beta biosynthesis byinducers of the heat-shock response. J Immunol.1988;141(6):2027~34
73Villar J,Edelson JD,Post M,et al,Induction of heat stress proteins isassociated with decreased mortality in an animal model of acute lunginjury. Am Rev Respir Dis.1993Jan;147(1):177~81
74Yoo CG,Lee S,Lee CT,et al,Anti-inflammatory effect of heat shock proteininduction is related to stabilization of IκBα through preventing IκB kinaseactivation in respiratory epithelial cells. J Immunol.2000;164(10):5416~5423
75Barnes PJ,Karin M.Nuclear factor-kappaB: a pivotal transcription factor inchronic inflammatory diseases. N Engl J Med.1997;336(15):1066~1071
76Gabai VL,Meriin AB,Mosser DD,et，al.Hsp70prevents activation of stresskinases. A novel pathway of cellular thermotolerance.J Biol.Chem.1997;272(29):18033~18037
77Meldrum KK,Meldrum DR,Sezen SF,et,al.Heat shock prevents simulatedischemia-induced apoptosis in renal tubular cells via a PKC-dependentmechanism. Am J Physiol Regul Integr Comp Physiol.2001Jul;281(1):R359~64
78Shibuya K,Kawasaki S,Kuroda M,et,al.Effects of PKC inhibitors onsuppression of thermotolerance development in tsAF8cells. Int JHyperthermia.2001;17(2):106~113
79Koroku M,Kumamoto Y,Hirose T.A study on the role of Chlamydiatrachomatis in chronic prostatitis--analysis of anti-Chlamydia trachomatisspecific IgA in expressed prostate secretion by western-blotting method.Kansenshogaku Zasshi.1995Apr;69(4):426~437
80郭辉，徐月敏，叶章群等，细胞因子及热休克蛋白在慢性前列腺炎患者精浆中的含量及其临床意义。中华男科学杂志，2012，18(12):1088~1092
81李火金，孙连杰，史明，精浆热休克蛋白表达与前列腺炎分型临床研究。中国煤炭工业医学杂志，2005，8（10）：1071~1072
2Nickel JC. The overlapping lower urinary tract symptoms of benignprostatic hyperplasia and prostatitis[J].Current Opinion in Urology2006,16,5~10
3Nickel JC.Inflammation and benign prostatic hyperplasia[J]. Urol Clin NAm2008,35,109~115
4Nickel JC, Downey J,Young I.et al. Asymptomatic inflammation and orinfection in benign prostatic hyperplasia[J]. BJU Int1999,84,976~981
5Nickel JC,Downey J,Pontari MA,et al.A randomized placebo-controlledmulticentre study to evaluate the safety and efficacy of finasteride for malechronic pelvic pain syndrome (category IIIA chronic nonbacterialprostatitis)[J]. BJU Int.2004,93,991~995
6St Sauver JL,Jacobson DJ,McGree ME.et al. Protective associationbetween nonsteroidal anti-inflammatory drug use and measures of benignprostatic hyperplasia[J].American Journal of Epidemiology2006,164,760~768
7McConnell JD,Roehrborn CG,Bautista OM, et al. The long term effect ofdoxazosine, finasteride and combination therapy on the clinicalprogression of benign prostatic hyperplasia[J]. New England Journal ofMedicine.2003,349,2387~2398
8Nickel JC,Roehrborn CG, O’Leary MP.et al. The relationship betweenprostate inflammation and lower urinary tract symptoms: examination ofbaseline data from the REDUCE trial[J]. European Urology.2007,54,1379~1384
9Mishra VC, Allen DJ, Nicolaou C, et al. Does intraprostatic inflammationhave a role in the pathogenesis and progression of benign prostatichyperplasia?[J] BJU Int2007;100:327~331
10Van Vuuren SP, Heyns CF, Zarrabi AD.Significance of histologicalprostatitis in patients with urinary retention and underlying benignprostatic hyperplasia or adenocarcinoma of the prostate [J].BJU Int,2012,109(8):1194~1197
11Sciarra A,Mariotti G,Salciccia S,et al.Prostate growth and inflammation[J].J Steroid Biochem Mol Biol2008;108:254~260
12Sciarra A, Di Silverio F, Salciccia S, et al. Inflammation and chronicprostatic diseases: evidence for a link?[J] Eur Urol2007;52:964~972
13Litwin MS,M cNaughton-Collins M,Fowler FJ Jr, et, al. The NationalInstitutes of Health chronic prostatitis symptom index (NIHCPSI):Development and validation of a new outcome measure[J]. JUrol,1999,162(2):369~375
14Nickel JC, True LD, Krieger JN, et al.Consensus development of ahistopathological classification system for chronic prostatic inflammation[J]. BJU Int,2001,87(9):797~805
15夏同礼.现代泌尿病理学.北京:人民卫生出版社,2002.477~480
16张祥华,张骞,李学松,等.良性前列腺增生合并组织学前列腺炎的检出率[J].中华临床医师杂志,2007,1(7):539~541
17Mishra VC,Allen DJ,Nicolaou C,et al.Does intraprostatic inflammationhave a role in the pathogenesis and progression of benign prostatichyperplasia？[J] BJU Int.2007;100(2):327~331
18Nadler RB, Humphrey PA, Smith DS, et al. Effect of inflammation andbenign prostatic hyperplasia on elevated serum prostate specific antigenlevels [J].J Urol.1995;154:407~413
19Nickel JC,Roehrborn CG,O’Leary MP,et al.Examination of therelationship between symptoms of prostatitis and histologicalinflammation: baseline data from the REDUCE chemoprevention trial [J].JUrol.2007;178:896~900
20Seyed AA, Mohaddeseh M. The Role of Intraprostatic Inflammation in theAcute Urinary Retention [J]. Int J Prev Med,2011,2(1):28~31
21Nickel JC, Roehrborn CG, O'Leary MP, et al. The relationship betweenprostate inflammation and lower urinary tract symptoms: examination ofbaseline data from the REDUCE trial[J].Eur Urol,2008,54(6):1379~1384.
22Devaraj S, Singh U, Jialal I.Human C-reactive protein and the metabolicsyndrome. Curr Opin Lipidol2009;20:182~189
23Martin-Cordero L, Garcia JJ, Giraldo E, De la Fuente M, Manso R, OrtegaE.Influence of exercise on the circulating levels and macrophageproduction of IL-1beta and IFN-gamma affected by metabolic syndrome:an obese Zucker rat experimental animal model. Eur J Appl Physiol2009;107:535~543
24Alexandraki K, Piperi C, Kalofoutis C, et al. Inflammatory process in type
2diabetes: the role of cytokines.Ann NY Acad Sci2006;1084:89~117
25Gustafson B, Hammarstedt A, Andersson CX, Smith U. Inflamed adiposetissue: a culprit underlying the metabolic syndrome and atherosclerosis.Arterioscler Thromb Vasc Biol2007;27:2276~2283
26Murdolo G, Smith U. The dysregulated adipose tissue:a connecting linkbetween insulin resistance, type2diabetes mellitus and atherosclerosis.Nutr Metab Cardiovasc Dis.2006;16(Suppl.1):S35~38
27Shun-Fa Hung, Shiu-Dong Chung, Hann-Chorng Kuo，Increased serumC-Reactive Protein level is associated with increased storage lower urinarytract symptoms in men with Benign Prostatic Hyperplasia.PLoS One.2014Jan15;9(1):e85588
28Liao CH,Chung SD,Kuo HC， Serum C-reactive protein levels areassociated with residual urgency symptoms in patients with benignprostatic hyperplasia after medical treatment.Urology.2011;78(6):1373~1378
29Jennifer L.St. Sauver, Aruna V. Sarma, Debra J Jacobson.Associationsbetween C-Reactive Protein and Benign Prostatic Hyperplasia Lowerurinary tract symptom outcomes in a population-based Cohort.Am JEpidemiol2009;169:1281~1290
30St Sauver JL,Jacobson DJ, McGree ME,et al. Protective associationbetween nonsteroidal antiinflammatory drug use and measures of benignprostatic hyperplasia.Am J Epidemiol.2006;164(8):760~768
31Falahatkar S,Mokhtari G,Pourreza F,et al.Celecoxib for treatment ofnocturia caused by benign prostatic hyperplasia: a prospective,randomized,double-blind,placebo-controlled study.Urology.2008;72(4):813~816
32VelaNavarreteR,GarciaCardosoJV A.BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatorymarkers.Results of a double blind pilot clinical assay.Eur Urol2003;44:549~55
1McVary KT. BPH: epidemiology and comorbidities.Am J Manag Care.2006;12(suppl5):S122~S128
2Roehrborn CG. BPH progression: concept and key learning from MTOPS,ALTESS, COMBAT,and ALF-ONE. BJU Int.2008;101(suppl3):17~21
3Vykhovanets EV, Resnick MI，Marengo SR. The healthy rat prostatecontains high levels of natural killer-like cells and unique subsets of CD4+helper-inducer T cells: implications for prostatitis.JUrol.2005;173(3):1004~1010
4Steiner GE, Stix U, Handisurya A.et al. Cytokine expression pattern inbenign prostatic hyperplasia infiltrating T cells and impact of lymphocyticinfiltration on cytokine mRNA profile in prostatic tissue. LaboratoryInvestigation.2003;83：1131~1146
5Sciarra, A., Di Silverio, F., Salsiccia, S,et al.Inflammation and chronicprostatic diseases:evidence for a link? European Urology2007，52,（4）964~972
6Penna G,Fibbi B,Amuchastegui S,et al. Human benign prostatichyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. J Immunol.2009;182(7):4056~4064
7Nadlcr RB，Koch AE，Calhoun EA，et a1．IL-1beta and TNF-alpha inprostatic secretions are indicators in the evaluation of men with chronicprostatitis.J Urol，2000，164(1)：214~218
8贺大林，周锋，何辉等，前列腺按摩液中IL一8和TNF-α测定在慢性前列腺炎诊断、分型中的临床意义。中华男科学杂志，2004,10；（10）740~742
9孙国华，宁方霞，夏玉军。IL一10、TNF-a在前列腺增生及前列腺癌组织中的表达及意义。泌尿外科杂志（电子版）2012，4（1）：25~28
10Pontari M．A，Ruggieri M．R．Mechanisms in prostatitis／chronic pelvicpain．J Urol，2008，179(supply5)：61~67
11Jeannette M. Schenk, Alan R. Kristal, Marian L. Neuhouser,,etal.Biomarkers of systemic inflammation and risk of incident, symptomaticbenign prostatic hyperplasia: results from the prostate cancer preventiontrial. Am J Epidemiol.2010;171(5):571~82
12Giri D, Ozen M，Ittman M.Interleukin-6is an autocrine growth factor inhuman prostate cancer. American Journal of Pathology.2001;159(6):2159~2165
13Royuela M,Ricote M,Parsons MS.et al.Immunohistochemical analysis ofthe IL-6family of cytokines and their receptors in benign hyperplasic, andmalignant human prostate. J Pathol.2004;202(1):41~49
14俞弘颀，孙清，张洲洲。血清白介素及肿瘤坏死因子-α水平在良性前列腺增生与慢性前列腺炎关系探讨中的价值。苏州大学学报（医学版），2008；28（6）：1070~1071
15Bouraoui Y,Ricote M,García-Tu ón I,et al.Pro-inflammatory cytokinesand prostate-specific antigen in hyperplasia and human prostate cancer.Cancer Detect Prev.2008;32(1):23~32
16李兴斌，王海峰，常丛旺。前列腺液IL-6、IL-8在诊断BPH合并CP的临床意义。西部医学，2012；24（2）：250~251
17De Nunzio C,Kramer G,Marberger M,et al. The controversial relationshipbetween benign prostatic hyperplasia and prostate cancer: the role ofinflammation. Eur Urol.2011;60(1):106~117
18Robert G, Descazeaud A, Nicolaiew N, et al. Inflammation in benignprostatic hyperplasia: a282patients immunohistochemical analysis.Prostate2009;69:1774~1780
19El Hentati FZ, Gruy F, Iobagiu C, et al. Variability of CD3MembraneExpression and T Cell Activation Capacity.Cytometry B ClinCytom.2010;78(2):105~114
20Park DS,Shim JY. Histologic influence of doxazosin and finasteride inbenign prostatic hyperplasia accompanying chronic inflammation. UrolInt.2008;81(4):441~446
21蓝儒竹，庄乾元，胡志全等，前列腺增生组织内炎症对前列腺微循环的影响。中华实验外科杂志，2009，26（10）：1366~1368
1Cornford PA, Dodson AR, Parsons KF, et al.Heat shock proteinexpression independently predicts clinical outcome in prostate cancer.Cancer Res2000;60:7099~7105
2Foster CS, Dodson AR, Ambroisine L, et al. Hsp-27expression atdiagnosis predicts poor clinical outcome in prostate cancer independent ofETS-gene rearrangement. Br J Cancer2009;101:1137~1144
3Glaessgen A,Jonmarker S,Lindberg A,et al.Heat shock proteins27,60and70as prognostic markers of prostate cancer.Apmis2008;116:888~895
4Miyake H, Muramaki M, Kurahashi T, et al.Expression of potentialmolecular markers in prostate cancer: correlation with clinicopathologicaloutcomes in patients undergoing radical prostatectomy. Urol Oncol2010;28:145~151
5Shiota M,Bishop JL,Nip KM,et al.Hsp27regulates epithelial mesenchymaltransition,metastasis, and circulating tumor cells in prostate cancer. CancerRes.2013,15(10):3109~3119
6N Vasiljevi,A S Ahmad,C Beesley,et al. Association between DNAmethylation of HSPB1and death in low Gleason score prostate cancer.Prostate Cancer Prostatic Dis.2013;16(1):35~40
7Zoubeidi A,Zardan A,Beraldi E,et al. Cooperative interactions betweenandrogen receptor(AR) and heat-shock protein27facilitate ARtranscriptionalactivity. Cancer Res.2007;67(21):10455~10465
8刘丽娜，牛晓东，李伟等，热休克蛋白27在前列腺癌中的表达及临床意义。解放军医药杂志，2012，24（9）20~22
9Welch WJ,How cells respond to stress.SCI Am.1993;268:56-64
10De Marzo AM, Platz, EA., Sutcliffe S,et al. Inflammation in prostatecarcinogenesis. Nat Rev Cancer2007;7（4）256~269
11陈月云，王伟华，于智勇等，非那雄胺对老年良性前列腺增生患者血清热休克蛋白和肿瘤坏死因子以及白细胞介素影响。中华老年医学杂志，2013；32（1）58~60
12Ali MM,Vaidya V.Vitamin D and cancer.J Cancer Res Ther.2007;3:225~230
13Penna G, Fibbi B, Amuchastegui S,et al.Human Benign prostatichyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. Journal of Immunology2009b,182:4056~4064
14Adorini L, Penna, G., Amuchastegui, S., et al. Inhibition of prostategrowth and inflammation by the vitamin D receptor agonist BXL-628(elocalcitol). Journal of Steroid Biochemistry and Molecular Biology2007；103:689~693
1McVary KT. BPH: epidemiology and comorbidities.Am J Manag Care.2006;12(suppl5):122~128
2Roehrborn CG. BPH progression: concept and key learning from MTOPS,ALTESS, COMBAT,and ALF-ONE.BJU Int.2008;101(suppl3):17~21
3Mishra VC,Allen DJ,Nicolaou C,et al. Does intraprostatic inflammationhave a role in the pathogenesis and progression of benign prostatichyperplasia?BJU Int.2007.Aug;100(2):327~331
4Nadler RB, Humphrey PA, Smith DS, et al. Effect of inflammation andbenign prostatic hyperplasia on elevated serum prostate specific antigenlevels. J Urol.1995;154:407~413
5Nickel JC, Roehrborn CG, O’Leary MP, et al. Examination of therelationship between symptoms of prostatitis and histologicalinflammation: baseline data from the REDUCE chemoprevention trial.JUrol.2007;178:896~900; discussion900~901
6Sciarra, A., Di Silverio, F., Salsiccia, S,et al.. Inflammation and chronicprostatic diseases: evidence for a link? European Urology2007，52,（4）964~972
7Penna G,Fibbi B,Amuchastegui S,et al.Human benign prostatichyperplasia stromal cells as inducers and targets of chronicimmuno-mediated inflammation. J Immunol.2009;182(7):4056~4064
8Zisman, A., Zisman, E., Lindner, A., Velikanov, S., Siegel, Y. I.&Mozes,E. Autoantibodies to prostate specific antigen in patients withbenign prostatic hyperplasia. Journal of Urology (1995)154,1052~1055
9Harrington, L. E., Mangan, P. R.&Weaver, C. T. Expandingthe effectorCD4T-cell repertoir: The Th17lineage. Current Opinion in Immunology.200618,349~356
10Krieger JN,Lee SW,Jeon J,et al. Epidemiology of prostatitis. InternationalJournal of Antimicrobial Agents.2008;31:85~90
11Pontari MA,Ruggieri MR. Mechanisms in prostatitis chronic pelvic painsyndrome. Journal of Urology。2008；179,61~67
12Harris MT,Feldberg RS,Lau KM.,et al. Expression of proinflamma torygenes during estrogeninduced inflammation of the rat prostate. Prostate,2000；44,19~25
13Naslund,M.J.Coffey,D.S.The differential effects of neonatal androgen,estrogen and progesterone on adult rat postate growth..J Urol1986,(136):1136~1140
14Kramer,G.,Mitteregger,D.Marberger,M.Is begign prostatic hyperplasia(BPH) an immune inflammatory disease?European Urology2007,(51):1202~1216
15Sandhu,J.S.Prostate cancer and chronic prostatitis.Curr UrolRep,2008;9(4):328~332
16J Riera CM,Rivero, VE. Presence of IFNc-secreting lymphocytes specificto prostate antigens in a group of chronic prostatitis patients. ClinImmunol.2005;116,149~157
17Vykhovanets, E. V., Resnick, M. I., MacLennan, G. T.&Gupta, S.Experimental rodent models of prostatitis: limitations and potential.Prostate Cancer Prostatic Dis.2007;10,15~29
18Nickel, J. C. Inflammation and benign prostatic hyperplasia. Urol Clin NAm.2008;35,109~115
19Krieger JN, Lee SW,Jeon J,et al.Epidemiology of prostatitis.International.Journal of Antimicrobial Agents.2008;31,85~90
20Alexander RB,Mann DL, Borkowski AA,et al. Granulomatous prostatitislinked to HLA-DRB1*1501. Journal of Urology.2004;171:2326~2329
21Klyushnenkova EN, Link J, Oberle WT,er al. Identification ofHLADRB1*1501-restricted T-cell epitopes from prostate-specificantigen.Clinical Cancer Research.2005;11:2853~2861
22Schwartz GG. Vitamin D and the epidemiology of prostate cancer. SeminDial.2005;18:276~289
23Ali MM,Vaidya,V. Vitamin D and cancer.J Cancer Res Ther2007;3:225~230
24Glenn Liu, George Wilding, Mary Jane Staab,et al.Phase II Study of1-Hydroxyvitamin D2in the Treatment of Advanced Androgen-independent Prostate Cancer.Clin Cancer Res.2003;9:4077~4083
25Maggi M,Crescioli C,Morelli A, er al. Pre-clinical evidence and clinicaltranslation of benign prostatic hyperplasia treatment by the vitamin Dreceptor agonist BXL-628，(Elocalcitol). Journal of EndocrinologicalInvestigation.2006;29,665~674
26Colli E, Rigatti P,Montorsi F,Artibani W,Petta S,Mondaini N.et al.BXL-628, a novel vitamin D3analog arrests prostate growth in patientswith benign prostatic hyperplasia: a randomized clinical trial. EuropeanUrology.2006;49:82~86
27Montorsi F,Colli E,Elocalcitol in the Treatment of BPH: A MulticenterRandomized Placebo-Controlled Phase IIb Clinical Trial. Abstract at theAmerican Urological Association Meeting.2008; Orlando, Florida, USA.
28Mishra VC,Allen DJ,Nicolaou C, et al. Does intraprostatic inflammationhave a role in the pathogenesis and progression of benign prostatichyperplasia? BJU Int.2007;100:327~331
29Nickel JC.Prostatic inflammation in benign prostatic hyperplasia-thethird component?Can J Urol.1994;1:1~4
30Nickel JC. Inflammation and benign prostatic hyperplasia.Urol Clin NorthAm.2008;35:109~115
31Roehrborn, C. G.Pathology of benign prostatic hyperplasia.InternationalJournal of Impotence Research2008,20,11~18
32Kobayashi, Y. The role of chemokines in neutrophil biology.FrontBiosci.2008;13:2400~2407
33Waugh DJ,Wilson C.The interleukin-8pathway in cancer.Clinical CancerResearch.2008;14:6735~6741
34Castro P,Xia C,Gomez L,Lamb DJ,Ittmann M. Interleukin-8expression isincreased in senescent prostatic epithelial cells and promotes thedevelopment of benign prostatic hyperplasia.Prostate.2004;60:153~159
35Schauer IG,Ressler SJ,Tuxhorn JA,et al. Elevated epithelial expression ofinterleukin-8correlates with myofibroblast reactive stroma in benignprostatic hyperplasia.Urology2008;72:205~213
36Penna G, Fibbi B, Amuchastegui S,et al. Human Benign prostatic hyper-plasia stromal cells as inducers and targets of chronic immuno-mediatedinflammation. Journal of Immunology2009b;182:4056~4064
37Penna G,Fibbi B,Amuchastegui S, et al. Human benign prostatichyperplasia stromal cells as inducers and targets of chronicimmune-mediated inflammation.. J Immunol.2009;182(7):4056~4064
38Robert G, Descazeaud A, Nicolaiew N, et al. Inflammation in benignprostatic hyperplasia: a282patients’ immunohistochemical analysis.Prostate.2009;69(16):1774~1780
39Rautajoki KJ,Kylaniemi MK, Raghav SK,et al. An insight into molecularmechanisms of human T helper cell differentiation. Annals of Medicine.2008;40:322~335
40Steiner GE,Djavan B,Kramer G,et al.The picture of the prostaticlymphokine network is becoming increasingly complex. Rev Urol2002;4:171~177
41Steiner GE,Stix U,Handisurya A.et al.Cytokine expression pattern inbenign prostatic hyperplasia infiltrating T cells and impact of lymphocyticinfiltration on cytokine mRNA profile in prostatic tissue.LaboratoryInvestigation.2003;(83):1131~1146
42Linda Vignozzi,Ilaria Cellai,Raffaella Santi,et al,Antiinflammatory effectof androgen receptor activation in human benign prostatic hyperplasiaells.Journal of Endocrinology.2012;214:31~43
43Robert G, Descazeaud A, Nicolaiew N, et al. Inflammation in benignprostatic hyperplasia: a282patients’ immunohistochemical analysis.Prostate.2009;69:1774~1780
44McDowell ME, Occhipinti S, Gardiner RA, et al.A review of prostate-specific antigen screening prevalence and risk perceptions for first-degreerelatives of men with prostate cancer. Eur J Cancer Care (Engl).2009;18:545~555
45Steiner GE, Newman ME, Paikl D, et al. Expression and function ofpro-inflammatory interleukin IL-17and IL-17receptor in normal, benignhyperplastic, and malignant prostate. Prostate.2003;56:171~182
46Descazeaud A，Weinbreck N，Ｒobert G，et al．Transforming growth factorbeta-receptor II protein expression in benign prostatic hyperplasia isassociateed with prostate volume and inflammation［J］BJU Int.2011;108(4):E23~28
47Sugar LM.Inflammation and prostate cancer.Can J Urol.2006;13(suppl1):46~47
48Di Silverio F, Gentile V, De Matteis A, et al.Distribution of inflammation,pre-malignant lesions, incidental carcinoma in histologically confirmedbenign prostatic hyperplasia: a retrospective analysis.Eur Urol.2003;43:164~175
49Falahatkar S, Mokhtari G, Pourreza F, et al. Celecoxib for treatment ofnocturia caused by benign prostatic hyperplasia: a prospective, randomized,double-blind, placebo-controlled study. Urology.2008;72:813~816
50Djavan B，Eckersberger E，Espinosa G，et al． Complex mechanisms inprostatic inflammatory response.［J］Eur Urol，2009，(Suppl8):872~878
51Naslund MJ，Strandberg JD，Coffey DS． The role of androgens andestrogens in the pathogenesis of experimental nonbacterial prostatitis.JUrol，1988，140:1049~1053
52Gervaix A, Galetto-Lacour A, Gueron T, Vadas L, Zamora S, Suter S, etal.Usefulness of procalcitonin and C-reactive protein rapid tests for themanagement of children with urinary tract infection. Pediatr Infect Dis J2001,20:507~511
53Lehrer S, Diamond EJ, Mamkine B, Droller MJ, Stone NN, et al Creactiveprotein is significantly associated with prostate-specific antigen andmetastatic disease in prostate cancer. BJU Int2005,95:961~962
54Shun-Fa Hung, Shiu-Dong Chung, Hann-Chorng Kuo，Increased SerumC-Reactive Protein Level Is Associated with Increased Storage LowerUrinary Tract Symptoms in Men with Benign Prostatic Hyperplasia.PLoSOne.2014Jan15;9(1):e85588
55Liao CH,Chung SD,Kuo HC， Serum C-reactive protein levels areassociated with residual urgency symptoms in patients with benignprostatichyperplasia after medical treatment.Urology.2011;78(6):1373~1378
56Jennifer L St Sauver,Aruna V Sarma, Debra J. Jacobson,.AssociationsBetween C-Reactive Protein and Benign Prostatic Hyperplasia LowerUrinary Tract Symptom Outcomes in a Population-based Cohort。Am JEpidemiol2009;169:1281~1290
57Devaraj S, Singh U, Jialal I. Human C-reactive protein and the metabolicsyndrome. Curr Opin Lipidol2009;20:182~189
58Martin-Cordero L, Garcia JJ, Giraldo E,et al. Influence of exercise on thecirculating levels and macrophage production of IL-1beta and IFNgammaaffected by metabolic syndrome: an obese Zucker rat experimental animalmodel. Eur J Appl Physiol2009;107:535~543
59Alexandraki K, Piperi C, Kalofoutis C,et al. Inflammatory process in type
2diabetes: the role of cytokines.Ann NY Acad Sci2006;1084:89~117
60Gustafson B, Hammarstedt A, Andersson CX, Smith U. Inflamed adiposetissue: a culprit underlying the metabolic syndrome and atherosclerosis.Arterioscler Thromb Vasc Biol2007;27:2276~2283
61Murdolo G, Smith U. The dysregulated adipose tissue:a connecting linkbetween insulin resistance, type2diabetes mellitus and atherosclerosis.Nutr Metab Cardiovasc Dis2006;16(Suppl.1): S35~38
62Bock E, Calugi V, Stolfi V, er al.Calcifications of the prostate: atransrectal echographic study. Radiol Med1989;77:501~503
63Shoskes DA, Lee CT, Murphy D, er al.Incidence and significance ofprostatic stones in men with chronic prostatitis/chronic pelvic painsyndrome.Urology2007;70:235~238
64Geramoutsos I, Gyftopoulos K, Perimenis P et al.Clinical correlation ofprostatic lithiasis with chronic pelvic pain syndromes in young adults. EurUrol2004;45:333~338
65Kwon YK, Choe MS, Seo KW, et al. The effect of intraprostatic chronicinflammation on benign prostatic hyperplasia treatment. Korean J Urol2010;51:266~270
66Hightower LE.Heat shock protein,chaperones and protectoxicity.Cell.1991;66:191~197
67Welch WJ,How cells respond to stress.SCI Am.1993;268:56~64
68Weiss YG,Maloyan A,Tazelaar J，Adenoviral transfer of HSP-70intopulmonary epithelium ameliorates experimental acute respiratory distresssyndrome.J Clin Invest.2002;110(6):801~806
69DeMaio A. Heat shock proteins, oxygen radicals, and apoptosis: theconflict between protection and destruction[J]. Critical care medicine,2000,28(5):1679.~1681
70Diamant S, Ben-Zvi AP,BukauB,etal. Size-dependent disaggregation ofstable protein aggregates by the DnaK chaperone machinery.J BiolChem,2000;275(28);21107~21113
71Thomas Laufen,Matthias P. Mayer,Christian Beisel,et al..Proc Natl AcadSci U S A.1999;96(10):5452~5457
72Schmidt JA,Abdulla E，Down-regulation of IL-1beta biosynthesis byinducers of the heat-shock response. J Immunol.1988;141(6):2027~34
73Villar J,Edelson JD,Post M,et al,Induction of heat stress proteins isassociated with decreased mortality in an animal model of acute lunginjury. Am Rev Respir Dis.1993Jan;147(1):177~81
74Yoo CG,Lee S,Lee CT,et al,Anti-inflammatory effect of heat shock proteininduction is related to stabilization of IκBα through preventing IκB kinaseactivation in respiratory epithelial cells. J Immunol.2000;164(10):5416~5423
75Barnes PJ,Karin M.Nuclear factor-kappaB: a pivotal transcription factor inchronic inflammatory diseases. N Engl J Med.1997;336(15):1066~1071
76Gabai VL,Meriin AB,Mosser DD,et，al.Hsp70prevents activation of stresskinases. A novel pathway of cellular thermotolerance.J Biol.Chem.1997;272(29):18033~18037
77Meldrum KK,Meldrum DR,Sezen SF,et,al.Heat shock prevents simulatedischemia-induced apoptosis in renal tubular cells via a PKC-dependentmechanism. Am J Physiol Regul Integr Comp Physiol.2001Jul;281(1):R359~64
78Shibuya K,Kawasaki S,Kuroda M,et,al.Effects of PKC inhibitors onsuppression of thermotolerance development in tsAF8cells. Int JHyperthermia.2001;17(2):106~113
79Koroku M,Kumamoto Y,Hirose T.A study on the role of Chlamydiatrachomatis in chronic prostatitis--analysis of anti-Chlamydia trachomatisspecific IgA in expressed prostate secretion by western-blotting method.Kansenshogaku Zasshi.1995Apr;69(4):426~437
80郭辉，徐月敏，叶章群等，细胞因子及热休克蛋白在慢性前列腺炎患者精浆中的含量及其临床意义。中华男科学杂志，2012，18(12):1088~1092
81李火金，孙连杰，史明，精浆热休克蛋白表达与前列腺炎分型临床研究。中国煤炭工业医学杂志，2005，8（10）：1071~1072